SCTL · Societal Cdmo, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $23.59M | $21.80M | $21.53M | - | $21.59M | $23.15M | $21.19M | - | $18.24M |
| Cost of Revenue | - | $19.87M | $17.33M | $19.28M | - | $16.05M | $17.47M | $16.11M | - | $13.16M |
| Gross Profit | - | $3.72M | $4.47M | $2.25M | - | $5.53M | $5.68M | $5.08M | - | $5.08M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | $5.31M | $5.27M | $4.66M | - | $5.08M | $5.16M | $5.71M | - | $4.61M |
| Total Operating Expenses | - | $25.35M | $22.77M | $24.13M | - | $21.37M | $22.85M | $22.05M | - | $17.90M |
| D&A | - | - | - | $1.91M | - | - | - | $1.79M | - | - |
| Operating Income | - | ($1.76M) | ($968.0K) | ($2.60M) | - | $215.0K | $302.0K | ($851.0K) | - | $336.0K |
| Interest Expense | - | $2.91M | $2.31M | $2.15M | - | $3.54M | $3.42M | $3.41M | - | $3.82M |
| Income Tax | - | $0 | $39.0K | $0 | - | - | - | - | - | - |
| Net Income | - | ($4.59M) | ($3.21M) | ($4.68M) | - | ($3.33M) | ($3.12M) | ($4.26M) | - | ($3.49M) |
| EPS - Basic | - | ($0.05) | ($0.04) | ($0.08) | - | ($0.07) | $0.03 | - | - | - |
| EPS - Diluted | - | ($0.05) | ($0.04) | ($0.08) | - | ($0.06) | $0.03 | - | - | - |
Balance Sheet
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.10M | $8.16M | $4.70M | $6.29M | $14.99M | $11.58M | $15.48M | $15.28M | $25.22M | $23.49M |
| Accounts Receivable | $16.58M | $14.77M | $15.52M | $15.23M | $15.95M | $17.10M | $16.52M | $14.12M | $11.91M | $13.75M |
| Inventory | $10.26M | $12.28M | $12.86M | $11.57M | $10.30M | $9.41M | $8.37M | $9.47M | $8.92M | $9.44M |
| Accounts Payable | $1.31M | $2.12M | $3.93M | $2.39M | $1.47M | $3.06M | $2.34M | $1.56M | $2.08M | $1.92M |
| Current Assets | $53.46M | $49.78M | $46.62M | $47.84M | $55.59M | $49.49M | $51.98M | $49.69M | $57.53M | $56.09M |
| Total Assets | $153.47M | $151.53M | $148.74M | $149.94M | $157.44M | $151.28M | $153.36M | $151.80M | $160.32M | $157.78M |
| Current Liabilities | $49.99M | $21.62M | $19.31M | $19.53M | $22.81M | $14.18M | $13.23M | $11.00M | $17.73M | $12.86M |
| Long-term Debt | $339.0K | $27.44M | $31.01M | $30.46M | $30.97M | $95.48M | $94.36M | $93.24M | $92.13M | $91.03M |
| Total Liabilities | $94.81M | $93.27M | $94.42M | $93.96M | $97.58M | $116.05M | $116.03M | $112.64M | $118.25M | $113.30M |
| Stockholders' Equity | $58.66M | $58.26M | $54.32M | $55.98M | $59.86M | $35.23M | $37.33M | $39.16M | $42.06M | $44.48M |
| Retained Earnings | ($278.91M) | ($278.12M) | ($273.53M) | ($270.32M) | ($265.63M) | ($256.47M) | ($253.14M) | ($250.02M) | ($245.75M) | ($243.40M) |
Cash Flow
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($2.85M) | - | - | - | ($89.0K) | - | - |
| Investing Cash Flow | - | - | - | ($3.38M) | - | - | - | ($1.71M) | - | - |
| Financing Cash Flow | - | - | - | ($2.47M) | - | - | - | ($153.0K) | - | - |
| CapEx | - | - | - | $3.38M | - | - | - | $1.71M | - | - |
| Free Cash Flow | - | - | - | ($6.23M) | - | - | - | ($1.80M) | - | - |
Ratios
| Metric | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 15.8% | 20.5% | 10.4% | - | 25.6% | 24.5% | 24.0% | - | 27.8% |
| Operating margin | - | -7.4% | -4.4% | -12.1% | - | 1.0% | 1.3% | -4.0% | - | 1.8% |
| EBITDA margin | - | - | - | -3.2% | - | - | - | 4.4% | - | - |
| Net margin | - | -19.5% | -14.7% | -21.8% | - | -15.4% | -13.5% | -20.1% | - | -19.1% |
| Free cash flow margin | - | - | - | -28.9% | - | - | - | -8.5% | - | - |
| FCF / Net income | - | - | - | 1.33 | - | - | - | 0.42 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | 22.5% | 24.2% | 21.7% | - | 23.5% | 22.3% | 26.9% | - | 25.3% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -3.0% | -2.2% | -3.1% | - | -2.2% | -2.0% | -2.8% | - | -2.2% |
| Return on equity | - | -7.9% | -5.9% | -8.4% | - | -9.4% | -8.4% | -10.9% | - | -7.8% |
| Return on invested capital | - | -1.6% | -0.9% | -2.4% | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.07 | 2.30 | 2.41 | 2.45 | 2.44 | 3.49 | 3.93 | 4.52 | 3.24 | 4.36 |
| Quick ratio | 0.86 | 1.73 | 1.75 | 1.86 | 1.99 | 2.83 | 3.30 | 3.66 | 2.74 | 3.63 |
| Cash ratio | 0.16 | 0.38 | 0.24 | 0.32 | 0.66 | 0.82 | 1.17 | 1.39 | 1.42 | 1.83 |
| Leverage | ||||||||||
| Debt / Equity | 0.01 | 0.47 | 0.57 | 0.54 | 0.52 | 2.71 | 2.53 | 2.38 | 2.19 | 2.05 |
| Debt / Assets | 0.00 | 0.18 | 0.21 | 0.20 | 0.20 | 0.63 | 0.62 | 0.61 | 0.57 | 0.58 |
| Debt / EBITDA | - | - | - | - | - | - | - | 99.09 | - | - |
| Interest coverage | - | -0.6x | -0.4x | -1.2x | - | 0.1x | 0.1x | -0.2x | - | 0.1x |
| Equity multiplier | 2.62 | 2.60 | 2.74 | 2.68 | 2.63 | 4.29 | 4.11 | 3.88 | 3.81 | 3.55 |
| Liabilities / Assets | 0.62 | 0.62 | 0.63 | 0.63 | 0.62 | 0.77 | 0.76 | 0.74 | 0.74 | 0.72 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.16 | 0.15 | 0.14 | - | 0.14 | 0.15 | 0.14 | - | 0.12 |
| Inventory turnover | - | 1.62 | 1.35 | 1.67 | - | 1.71 | 2.09 | 1.70 | - | 1.39 |
| Days sales outstanding | - | 229d | 260d | 258d | - | 289d | 261d | 243d | - | 275d |
| Days inventory outstanding | - | 226d | 271d | 219d | - | 214d | 175d | 215d | - | 262d |
| Days payable outstanding | - | 39d | 83d | 45d | - | 69d | 49d | 35d | - | 53d |
| Cash conversion cycle | - | 415d | 448d | 432d | - | 434d | 386d | 423d | - | 484d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 9.3% | -5.8% | 1.6% | - | 18.4% | 28.5% | 26.1% | - | -5.4% |
| Revenue CAGR (3y) | - | 6.9% | 12.0% | -0.4% | - | -5.1% | -9.5% | -5.4% | - | 2.1% |
| Revenue CAGR (5y) | - | 6.6% | 5.2% | 2.0% | - | 4.8% | 6.5% | 2.5% | - | 1.5% |
| Gross profit growth (YoY) | - | -32.8% | -21.3% | -55.7% | - | 9.0% | -0.0% | 106.0% | - | -32.7% |
| Operating income growth (YoY) | - | - | - | -205.3% | - | -36.0% | -83.6% | 70.3% | - | -86.5% |
| Net income growth (YoY) | - | -37.9% | -3.0% | -9.8% | - | 4.5% | - | 36.9% | - | -63.9% |
| EPS growth (YoY) | - | 16.7% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -246.6% | - | - | - | -14.8% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -2.0% | 65.3% | 45.5% | 42.9% | 42.3% | -20.8% | 41.3% | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Societal CDMO against the 5 most active filers in the same SIC group.